G12D MUTATED KRAS

Clinical trials for G12D MUTATED KRAS explained in plain language.

Never miss a new study

Get alerted when new G12D MUTATED KRAS trials appear

Sign up with your email to follow new studies for G12D MUTATED KRAS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New pill targets 'Undruggable' cancer mutation in major trial

Disease control Recruiting now

This early-stage study is testing a new oral drug called VS-7375, which is designed to block a specific cancer-driving mutation known as KRAS G12D. Researchers will give the drug alone and in combination with other cancer therapies to adults with advanced solid tumors, including …

Matched conditions: G12D MUTATED KRAS

Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control

Last updated Mar 27, 2026 12:40 UTC

G12D MUTATED KRAS

Get alerted when new G12D MUTATED KRAS trials appear

New pill targets 'Undruggable' cancer mutation in major trial